Haemonetics-HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up

Haemonetics Corporation (HAE) delivered fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.24, which rose 37.8% year over year. The bottom line topped the Zacks Consensus Estimate by 1.6%. On a GAAP basis, EPS was$ 1.17 compared with 40 cents in the prior-year quarter. Full-year fiscal 2025 adjusted EPS was $4.57, which rose 15.4% year over year. Following the earnings announcement, shares of HAE rose 0.3% last Friday. HAE's Revenues Revenues decreased 3.7% to$ 330.6 million, which surpassed ...